OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

Basilea Pharmaceutica AG BASILEA .../  CH0011432447  /

London International
2024-05-24  4:57:06 PM Chg. - Volume Bid6:00:05 AM Ask6:00:05 AM Market Capitalization Dividend Y. P/E Ratio
43.65CHF - 604
Turnover: 1,788.45		 -Bid Size: - -Ask Size: - 531.85 mill.CHF - 46.67
GlobeNewswire 7:15 AM Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Newsfile Corp 06-18 GNQ Insilico's AI-Driven Digital Twin Platform Shows Promising Results in First Virtually Simulated ...
GlobeNewswire 06-02 Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT...
GlobeNewswire 05-28 NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire 05-22 Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
GlobeNewswire 05-21 Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipelin...
GlobeNewswire 05-16 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 05-14 NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 f...
GlobeNewswire 05-03 Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire 04-24 NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
GlobeNewswire 04-24 Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire 04-17 Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
GlobeNewswire 04-09 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire 04-04 Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire 04-02 Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for t...
GlobeNewswire 03-11 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire 02-13 Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
GlobeNewswire 02-13 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire 01-29 Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Pha...
GlobeNewswire 01-19 Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire 01-15 Basilea announces acquisition of preclinical antibiotics program from Spexis
GlobeNewswire 01-05 Basilea provides portfolio status update
GlobeNewswire 2023-12-26 Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China ...
GlobeNewswire 2023-12-26 LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
GlobeNewswire 2023-12-11 Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...